TerminatedNCT01944839
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
PHASE3 · 619 planned enrolment
- Countries listed
- 13
- Registry update
- October 30, 2024
